Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BHVN Biohaven Pharmaceutical Holding Company Ltd. daily Stock Chart
BHVN [NYSE]
Biohaven Pharmaceutical Holding Company Ltd.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-12.62 Insider Own4.30% Shs Outstand56.41M Perf Week10.17%
Market Cap3.48B Forward P/E- EPS next Y-6.88 Insider Trans-18.10% Shs Float48.09M Perf Month36.56%
Income-639.40M PEG- EPS next Q-2.50 Inst Own97.21% Short Float21.98% Perf Quarter38.14%
Sales1.20M P/S2902.98 EPS this Y-77.40% Inst Trans18.71% Short Ratio11.26 Perf Half Y11.57%
Book/sh2.16 P/B29.78 EPS next Y30.60% ROA-141.60% Target Price63.00 Perf Year13.92%
Cash/sh7.91 P/C8.14 EPS next 5Y- ROE-608.60% 52W Range26.56 - 67.86 Perf YTD18.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.22% Beta-
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin63.20% 52W Low142.17% ATR3.63
Employees647 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)76.14 Volatility7.64% 6.77%
OptionableYes Debt/Eq2.36 EPS Q/Q-117.70% Profit Margin- Rel Volume1.05 Prev Close62.47
ShortableYes LT Debt/Eq2.36 Earnings- Payout- Avg Volume938.64K Price64.32
Recom1.80 SMA2025.70% SMA5051.31% SMA20039.60% Volume990,306 Change2.96%
Apr-17-20Initiated Cowen Outperform $45
Feb-10-20Downgrade Oppenheimer Outperform → Perform
Feb-06-20Initiated Mizuho Buy
Nov-22-19Initiated Wedbush Outperform
Jun-25-19Reiterated Canaccord Genuity Buy $89 → $84
May-06-19Initiated Goldman Buy $92
Apr-09-19Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19Reiterated Needham Buy $48 → $56
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
Jun-01-20 04:05PM  
Kleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare Conference
GlobeNewswire
May-28-20 06:46AM  
3 Reasons Why Biohaven Pharmaceuticals' Stock Is Taking Off
Motley Fool
May-21-20 07:30AM  
Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma
GlobeNewswire
May-18-20 07:30AM  
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
PR Newswire +6.81%
May-15-20 07:33AM  
Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting
GlobeNewswire +6.66%
May-07-20 04:10PM  
Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments
PR Newswire
May-04-20 08:47AM  
Why Biohaven (BHVN) Might Surprise This Earnings Season
Zacks +8.34%
Apr-27-20 07:30AM  
Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC ODT in the Middle East
PR Newswire
Apr-16-20 05:42PM  
Biohaven Changing 2020 Annual Meeting Of Shareholders To Virtual-Only Meeting Format Due To COVID-19
PR Newswire
07:30AM  
Biohaven Enters Into Partnership With Medison Pharma To Distribute NURTEC ODT In Israel
PR Newswire
Apr-09-20 10:01AM  
Biohaven Pharmaceutical Needs More Bottom Development Before Becoming a Buy
TheStreet.com +7.38%
07:30AM  
Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection
PR Newswire
Apr-07-20 07:48AM  
Does Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Have A High Beta?
Simply Wall St. -5.77%
07:30AM  
Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC ODT
PR Newswire
Mar-31-20 07:33AM  
Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy
PR Newswire
Mar-30-20 07:30AM  
Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC, Dosed Every Other Day, for the Preventive Treatment of Migraine
PR Newswire -5.58%
Mar-29-20 08:21PM  
Hedge Funds Are Souring On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Insider Monkey
Mar-23-20 07:30AM  
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
PR Newswire
Mar-18-20 07:30AM  
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
PR Newswire
Mar-13-20 07:30AM  
Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults
PR Newswire +5.80%
Mar-12-20 04:30PM  
Biohaven's NURTEC ODT (rimegepant 75mg) is Now Available in U.S. Pharmacies for the Acute Treatment of Migraine in Adults
PR Newswire -14.80%
Mar-04-20 09:55AM  
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
Zacks +6.23%
Feb-28-20 07:28AM  
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
Benzinga +8.18%
Feb-27-20 04:11PM  
Biohaven's NURTEC ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults
PR Newswire -8.54%
Feb-25-20 04:45PM  
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments
PR Newswire
Feb-14-20 07:33AM  
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
PR Newswire
Feb-11-20 11:27AM  
3 Beaten-Down Biotech Stocks With +50% Upside Potential
TipRanks
Feb-10-20 04:17PM  
Biotech Stock Crumbles After Drug Fails To Pass Muster In Anxiety
Investor's Business Daily -8.18%
08:10AM  
Biohaven's investigational anxiety drug fails in trial
MarketWatch
07:30AM  
Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List
PR Newswire
07:25AM  
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
PR Newswire
Feb-06-20 07:33AM  
Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic
PR Newswire
Feb-04-20 10:22AM  
Analysts Forecast Huge Upsides for Aimmune, Biohaven
GuruFocus.com +6.56%
Jan-31-20 05:00PM  
Biohaven Appoints Michael Heffernan To Board Of Directors
PR Newswire
Jan-30-20 09:02AM  
Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock
Zacks
Jan-29-20 07:34AM  
Biohaven Announces Pricing Of $250 Million Public Offering Of Common Shares
PR Newswire -9.82%
Jan-28-20 05:13PM  
Biohaven Announces Proposed Public Offering Of Common Shares
PR Newswire +5.99%
Jan-23-20 07:24AM  
The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment
Benzinga
Jan-19-20 10:23AM  
3 Monster Growth Stocks That Can Rip Higher in 2020
TipRanks
Jan-16-20 01:45PM  
Hedge Fund Ardsley Partners Top Stock Picks
Insider Monkey
Dec-26-19 11:45AM  
How Did Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Compare Against Hedge Fund Darlings in 2019?
Insider Monkey
08:40AM  
Options Traders Expect Huge Moves in Biohaven (BHVN) Stock
Zacks
Dec-18-19 07:33AM  
Kleo Pharmaceuticals to Present at Biotech Showcase 2020
PR Newswire
Dec-17-19 07:30AM  
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
PR Newswire
Dec-15-19 07:41AM  
Have Insiders Been Buying Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Shares?
Simply Wall St.
Dec-06-19 04:32PM  
This Biotech Says Its Alzheimer's Drug Isn't Futile And Shares Pop
Investor's Business Daily
08:29AM  
UPDATE 2-Biohaven Pharma to continue late-stage study of Alzheimer's treatment
Reuters
07:51AM  
Biohaven Pharma to continue late-stage study of Alzheimer's treatment
Reuters
07:39AM  
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
Benzinga
07:30AM  
Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study
PR Newswire
Dec-05-19 05:43PM  
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office
PR Newswire
Dec-04-19 08:31PM  
Do Hedge Funds Love Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
Insider Monkey
Dec-02-19 07:33AM  
Kleo Pharmaceuticals to Present at Piper Jaffray 31st Annual Healthcare Conference
PR Newswire
Nov-13-19 01:00PM  
Biohaven Readies for David Versus Goliath Battle with Allergan
Bloomberg
Nov-06-19 09:02AM  
Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting
PR Newswire
Nov-05-19 07:30AM  
Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole
PR Newswire
Nov-04-19 06:43PM  
Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
PR Newswire
Nov-01-19 04:15PM  
Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments
PR Newswire
Oct-28-19 07:30AM  
Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
PR Newswire
Oct-26-19 09:35PM  
Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Insider Monkey
Sep-18-19 07:30AM  
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
PR Newswire
Sep-10-19 07:30AM  
Biohaven Advances NOJECTION Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
PR Newswire
Sep-09-19 07:30AM  
Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session
PR Newswire
Aug-08-19 05:02PM  
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
PR Newswire
Aug-07-19 07:30AM  
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
PR Newswire
Jul-31-19 07:30AM  
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
PR Newswire
Jul-24-19 04:30AM  
Release Your 'Inner Spock' When Investing in Biotech Stocks
TheStreet.com
Jul-22-19 07:30AM  
Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
PR Newswire
Jul-19-19 06:59PM  
Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod
Reuters
06:10PM  
Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study
PR Newswire
Jul-15-19 10:22AM  
Biohaven reveals positive results in migrane drug trial
Yahoo Finance Video +7.53%
07:30AM  
Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
PR Newswire
Jul-11-19 07:30AM  
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
PR Newswire
07:30AM  
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
PR Newswire
06:17AM  
The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
Benzinga
Jul-10-19 05:00PM  
Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
PR Newswire
04:30AM  
2 Single Hitters That Could Score With the 'Write' Strategy
TheStreet.com
Jul-05-19 02:05PM  
Biohaven Offering Seems to Make Sale Less Likely
GuruFocus.com
Jul-02-19 12:15PM  
Weekly CFO Buys Highlight
GuruFocus.com
Jul-01-19 07:30AM  
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
PR Newswire
Jun-26-19 11:15PM  
Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Bought $201,100 of Shares
GuruFocus.com +5.60%
Jun-24-19 07:30AM  
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
PR Newswire
Jun-18-19 10:07PM  
Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares
PR Newswire -23.61%
01:05PM  
Migraine-Drug Deal Hype Turns Into a Giant Headache
Bloomberg
12:40PM  
Here's Why Biohaven Pharmaceutical Plummeted Today
Motley Fool
07:31AM  
The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
Benzinga
07:05AM  
Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit?
Simply Wall St.
Jun-17-19 06:00PM  
Biohaven Announces Proposed Public Offering Of Common Shares
PR Newswire -8.92%
Jun-14-19 12:03PM  
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Investor's Business Daily
Jun-11-19 01:50PM  
Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Insider Monkey
11:53AM  
Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock
Zacks
May-07-19 11:30PM  
Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal Antibodies
PR Newswire
11:15PM  
Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
PR Newswire
06:55AM  
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
PR Newswire
May-03-19 07:30AM  
Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event
PR Newswire
May-02-19 01:21PM  
These 6 biotech stocks are promising takeover targets
MarketWatch
12:41PM  
Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Insider Monkey
Apr-26-19 06:10AM  
Analysts point to potential Biogen M&A options after Alzheimer's failure
American City Business Journals
Apr-16-19 08:10AM  
The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
Benzinga
Apr-15-19 08:43AM  
Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options
Zacks
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHILDS JOHN WDirectorApr 07Sale31.91200,0006,381,0322,476,938Apr 08 09:42 PM
CHILDS JOHN WDirectorApr 06Sale31.25150,0004,686,9372,676,938Apr 08 09:42 PM
AGUIAR ERICDirectorJan 22Option Exercise35.592,02171,9213,271Jan 24 06:43 PM
AGUIAR ERICDirectorJan 22Sale56.482,021114,1521,250Jan 24 06:43 PM
AGUIAR ERICDirectorJan 09Option Exercise9.2930,000278,70030,000Jan 10 07:46 PM
Gentile KimberlySVP, Clinical OperationsJan 09Option Exercise31.321,59049,8063,639Jan 10 07:46 PM
AGUIAR ERICDirectorJan 09Sale56.3930,0001,691,7000Jan 10 07:46 PM
Stock ElyseChief Medical OfficerJan 08Option Exercise55.9193752,388937Jan 10 07:46 PM
AGUIAR ERICDirectorJan 08Option Exercise55.911,25069,8881,250Jan 10 07:46 PM
Berman RobertSpecial Projects & Med OvrsghtDec 30Option Exercise0.61125,00076,250125,341Dec 31 07:33 PM
Berman RobertSpecial Projects & Med OvrsghtDec 30Sale53.22125,0006,652,052341Dec 31 07:33 PM
Stock ElyseChief Medical OfficerDec 18Option Exercise0.003,37503,375Dec 20 09:41 PM
Conway CharlesChief Scientific OfficerDec 18Option Exercise0.003,00007,000Dec 20 09:42 PM
Berman RobertSpecial Projects & Med OvrsghtDec 18Option Exercise0.006250625Dec 20 09:42 PM
Gentile KimberlySVP, Clinical OperationsDec 18Option Exercise0.003,75003,750Dec 20 09:40 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseDec 18Option Exercise0.003,00003,000Dec 20 09:40 PM
Tilton JohnCCO-Rare & Neurologic DisorderDec 18Option Exercise0.001,25001,250Dec 20 09:41 PM
Coric VladChief Executive OfficerDec 18Option Exercise0.0010,950010,950Dec 20 09:39 PM
Engelhart JamesChief Financial OfficerDec 18Option Exercise0.003,70006,200Dec 20 09:39 PM
AGUIAR ERICDirectorDec 16Option Exercise20.793,53773,5343,537Dec 18 09:39 PM
AGUIAR ERICDirectorDec 16Sale55.133,537194,9850Dec 18 09:39 PM
AGUIAR ERICDirectorDec 09Option Exercise20.794,07284,6574,072Dec 11 09:43 PM
AGUIAR ERICDirectorDec 09Sale55.114,072224,4110Dec 11 09:43 PM
GREGORY JULIA PDirectorNov 22Option Exercise23.6312,000283,56012,000Nov 22 09:30 PM
AGUIAR ERICDirectorNov 22Option Exercise37.541,25046,9251,250Nov 22 09:37 PM
AGUIAR ERICDirectorNov 22Sale55.241,25069,0500Nov 22 09:37 PM
GREGORY JULIA PDirectorNov 22Sale54.7512,000656,9570Nov 22 09:30 PM
Gentile KimberlySVP, Clinical OperationsNov 21Option Exercise0.6121,06512,85021,065Nov 22 09:36 PM
Gentile KimberlySVP, Clinical OperationsNov 21Sale53.0421,0651,117,2050Nov 22 09:36 PM
Gentile KimberlySVP, Clinical OperationsNov 20Option Exercise0.613,9352,4003,935Nov 22 09:36 PM
AGUIAR ERICDirectorNov 20Option Exercise32.426,729218,1546,729Nov 22 09:37 PM
AGUIAR ERICDirectorNov 20Sale52.206,729351,2340Nov 22 09:37 PM
Gentile KimberlySVP, Clinical OperationsNov 20Sale53.033,935208,6650Nov 22 09:36 PM
Stock ElyseChief Medical OfficerOct 18Option Exercise10.8217,700191,51417,700Oct 25 08:39 PM
Stock ElyseChief Medical OfficerOct 18Sale45.0717,700797,7500Oct 25 08:39 PM
Stock ElyseChief Medical OfficerOct 15Option Exercise10.828008,656800Oct 17 06:29 PM
Stock ElyseChief Medical OfficerOct 15Sale45.0180036,0080Oct 17 06:29 PM
AGUIAR ERICDirectorSep 11Option Exercise25.5110,000255,10010,000Sep 13 04:34 PM
AGUIAR ERICDirectorSep 11Sale45.0010,000450,0000Sep 13 04:34 PM
Bailey GregoryDirectorAug 20Buy37.655,000188,2502,587,601Aug 21 04:11 PM
Engelhart JamesChief Financial OfficerJun 27Buy43.052,500107,6252,500Jun 28 07:11 AM
Berman RobertChief Medical OfficerJun 27Buy42.302,500105,750240,500Jun 28 07:09 AM
Coric VladChief Executive OfficerJun 26Buy40.225,000201,10019,130Jun 26 09:28 PM
CHILDS JOHN WDirectorJun 26Buy40.3710,000403,70010,000Jun 26 08:40 PM
open in yahoo | open in reuters | open in google